Evidence map›Paper›PMID 16184415›Full record

ArticleDigestive diseases and sciences2005

Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats.

Takako Nakashima, Takashi Maeda, Hisashi Nagamoto, Takeshi Kumakura, Masaaki Takai, Toyoki Mori

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Ultrasound-mediated gastrointestinal drug delivery.Science translational medicine · 2015
    Article
  5. Article
  6. Article
  7. Article
  8. Wound healing of intestinal epithelial cells.World journal of gastroenterology · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Takako NakashimaResearch Institute of Pharmacological and Therapeutical Development, Otsuka Pharmaceutical Co. Ltd., Tokushima 771-0192, Japan.
Takashi Maeda
Hisashi Nagamoto
Takeshi Kumakura
Masaaki Takai
Toyoki Mori

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated therapeutic efficacy of rebamipide using dextran sulfate sodium (DSS) induced colitis model in rats. Three percent DSS solution was given to rats for 9 days. After that, we evaluated the drug efficacy on colitis sustained with continuous drinking of 1% DSS. Twice-daily treatment with 0.3% or 1% rebamipide for 14 days significantly ameliorated the stool abnormality in the colitis model, preferentially suppressed hematochezia. The colonic mucosal lesion, determined by Alcian blue staining on day 24, was significantly reduced by rebamipide enema in a dose-dependent manner. Either rebamipide or 5-aminosalycilic acid (5-ASA) enema treated once daily significantly ameliorated colitis. The minimum effective dose of rebamipide was 0.3% in once-daily treatment, and that of 5-ASA was 10%. In a mechanistic study, the epithelial cell sheet formation of the T84 colon cancer cell was measured as an increase in generation of trans-epithelial electrical resistance in vitro. Rebamipide accelerated the increase, while 5-ASA conversely suppressed it. These results suggest that rebamipide enema is effective for treatment of experimental ulcerative colitis (UC).

Indexed as

AlanineAnimalsAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsColitis, UlcerativeDextran SulfateDisease Models, AnimalDose-Response Relationship, DrugEnemaIndicators and ReagentsMaleMesalamineQuinolonesRatsRats, Sprague-DawleyAlanineAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsDextran SulfateIndicators and ReagentsMesalamineQuinolonesrebamipide

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.